In this large single-center cohort of 470 primary TaG1 low and intermediate risk BC with long-term follow-up, we found that half of the patients with disease progression did not experience any prior tumor recurrence resulting in the absence of association between the two outcomes, even for patients with multiple (>4) recurrences. This evidence concerns the gene CNTN2 and breast cancer.